Haemonetics Corporation
HAE
$57.17
$0.280.49%
NYSE
| 12/28/2024 | 09/28/2024 | 06/29/2024 | 03/30/2024 | 12/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.66% | 8.59% | 7.98% | 12.77% | 10.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.66% | 8.59% | 7.98% | 12.77% | 10.14% |
| Cost of Revenue | -1.78% | 4.53% | 5.41% | 10.12% | 3.19% |
| Gross Profit | 8.10% | 12.10% | 10.19% | 15.03% | 16.56% |
| SG&A Expenses | -0.34% | -3.09% | -2.26% | 16.41% | 12.20% |
| Depreciation & Amortization | 76.96% | 69.81% | 66.88% | 30.74% | -14.45% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.87% | 4.45% | 4.83% | 12.28% | 5.83% |
| Operating Income | 12.07% | 35.35% | 23.08% | 15.52% | 36.17% |
| Income Before Tax | 13.37% | 36.16% | -9.45% | -28.24% | 4.27% |
| Income Tax Expenses | -2.85% | 37.22% | -20.93% | -6.04% | 37.80% |
| Earnings from Continuing Operations | 20.02% | 35.82% | -6.50% | -30.68% | -5.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.02% | 35.82% | -6.50% | -30.68% | -5.17% |
| EBIT | 12.07% | 35.35% | 23.08% | 15.52% | 36.17% |
| EBITDA | 15.28% | 32.13% | 24.34% | 17.63% | 23.37% |
| EPS Basic | 21.16% | 35.38% | -7.23% | -31.16% | -5.64% |
| Normalized Basic EPS | 0.87% | 25.83% | 40.39% | 6.79% | 34.28% |
| EPS Diluted | 21.31% | 37.50% | -7.50% | -29.84% | -4.69% |
| Normalized Diluted EPS | 1.52% | 26.64% | 40.90% | 7.12% | 34.35% |
| Average Basic Shares Outstanding | -0.95% | 0.34% | 0.79% | 0.68% | 0.51% |
| Average Diluted Shares Outstanding | -1.57% | -0.30% | 0.44% | 0.37% | 0.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |